Avoro Capital Advisors Reduces $41M in Sarepta Therapeutics, Inc. ($SRPT)

Avoro Capital Advisors has completely exited its position in Sarepta Therapeutics, Inc. (NasdaqGS: SRPT), according to its latest 13F filing with the SEC. The fund sold all 2,674,835 shares it previously held, marking a 100% reduction in its stake.

What Changed in Avoro Capital Advisors' Sarepta Therapeutics Position

Avoro Capital Advisors cut its entire position in Sarepta Therapeutics, selling off 2,674,835 shares. This move reduced its holdings to zero shares, reflecting a complete exit from the stock.

Other Institutional Activity in Sarepta Therapeutics

In the same period, BlackRock, Inc. increased its holdings in Sarepta by 472,024 shares, bringing its total to 14,755,277 shares valued at approximately $321.1 million. Vanguard Portfolio Management LLC established a new position with 6,640,692 shares worth about $144.5 million. State Street Corp added 13,873 shares, ending with 6,613,314 shares valued at $143.9 million. Meanwhile, AQR Capital Management LLC reduced its holdings by 1,363,423 shares, holding 6,433,112 shares valued at around $138.6 million. Two Sigma Investments, LP nearly doubled its stake, adding 2,151,740 shares to hold 4,593,195 shares worth $99.9 million.

Sarepta Therapeutics Stock Snapshot

Shares of Sarepta Therapeutics are trading around $15.31. The company has a market capitalization of $1.62 billion and a forward P/E ratio of 5.62. Sarepta's beta is relatively low at 0.205, suggesting less volatility compared to the market. The stock's 52-week range is between $10.42 and $25.32. It has a 50-day moving average of $19.3 and a 200-day moving average of $19.75. The company maintains a strong current ratio of 4.63 and a quick ratio of 2.41, with a debt-to-equity ratio of 69.57.

Recent Earnings

Sarepta Therapeutics reported revenues of $2.18 billion, though it saw a slight decline in revenue growth at -1.9%. Its earnings per share (EPS) is $0.35, with a net margin of 2.98% and a return on equity (ROE) of 4.91%. The company is expected to announce its next earnings on August 5, 2026.

Insider Buying and Selling at Sarepta Therapeutics, Inc.

On June 4, 2026, several insiders bought shares of Sarepta. Michael Andrew Chambers, Deirdre Connelly, Kathryn Jean Boor, Hans Lennart Rudolf Wigzell, Richard Barry, and Claude Nicaise each acquired 16,875 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On March 26, 2026, Citigroup maintained its sell rating on Sarepta with a price target of $13. Oppenheimer reiterated a buy rating with a target of $37 on March 19, 2026. Mizuho also maintained a buy rating, setting a target of $31 on March 13, 2026. The consensus among 23 analysts is a target mean price of $22.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing RNA-targeted therapeutics and gene therapies for rare diseases. The company offers treatments such as EXONDYS 51, VYONDYS 53, and AMONDYS 45 for Duchenne muscular dystrophy. Sarepta is also working on gene therapy programs for other genetic disorders. The company collaborates with several partners, including F. Hoffman-La Roche and Nationwide Children's Hospital.

Bottom Line

Avoro Capital Advisors' complete exit from Sarepta Therapeutics is a notable move that investors will watch closely. Sarepta continues to show potential in the biotechnology sector, with ongoing research and development efforts. Remember, 13F filings are historical and may not reflect current positions.